Guard Therapeutics
29 SEK 0%Be the first to follow this company
Guard Therapeutics is a developer of pharmaceuticals in the field of oxidative stress. The company focuses primarily on the research, development, and commercialization of pharmaceuticals that are intended to prevent the occurrence and complications of acute kidney damage. In preclinical studies, pharmaceuticals have been shown to protect exposed tissue and support regenerative processes. Treatment of acute kidney injuries in conjunction with heart surgery is a priority in clinical development.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GUARD
Daily low / high price
28.6 / 29.6
SEK
Market cap
349.62M SEK
Turnover
47.75K SEK
Volume
1.6K
Financial calendar
Interim report
22.08.2024
Interim report
13.11.2024
Annual report
20.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Jan Ståhlberg | 16.4 % | 16.4 % |
M2 Asset Management AB | 11.0 % | 11.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Guard Therapeutics research published in American Journal of Physiology – Renal Physiology
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools